The clinical, social and economic value of vaccination varies both with time and by population group
In most wealthy and in many middle income countries, capsular group B Neisseria meningitidis (MenB) remains an important cause of invasive disease, particularly in the era of control of other major bacterial pathogens, such as MenC, Haemophilus influenzae type b, and vaccine-type pneumococcus. Two new MenB vaccines1,2 (now licensed in many countries) provide the potential for a comprehensive approach to controlling these invasive bacterial pathogens. However, decisions about vaccination at the population level are complex when there are low rates of disease: cost-effectiveness is a particularly important factor.3
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307: 573-582.
- 2. Marshall HS, Richmond PC, Beeslaar J, et al. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2017; 17: 58-67.
- 3. Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ 2014; 349: g5725.
- 4. Archer BN, Chiu CK, Jayasinghe SH, et al. Epidemiology of invasive meningococcal B disease in Australia, 1999–2015: priority populations for vaccination. Med J Aust 2017; 207: 382-387.
- 5. Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine 2017; 35: 2034-2041.
- 6. Norheim G, Sadarangani M, Omar O, et al. Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis. BMJ Open 2014; 4: e003312.
- 7. Patel MS. Australia’s century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust 2007; 186: 136-141. <MJA full text>
- 8. Buckee CO, Jolley KA, Recker M, et al. Role of selection in the emergence of lineages and the evolution of virulence in Neisseria meningitidis. Proc Natl Acad Sci USA 2008; 105: 15082-15087.
- 9. Campbell H, Ladhani S. The importance of surveillance: Group W meningococcal disease outbreak response and control in England. Int Health 2016; 8: 369-371.
- 10. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis 2015; 60: 578-585.
- 11. National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases. Meningococcal disease. Meningococcal vaccines for Australians: information for immunisation providers [fact sheet]. Mar 2017. http://www.ncirs.edu.au/assets/provider_resources/fact-sheets/meningococcal-vaccines-fact-sheet.pdf (accessed July 2017).
- 12. Ladhani SN, Ramsay M, Borrow R, et al. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child 2016; 101: 91-95.
- 13. Parikh SR, Campbell H, Beebeejaun K, et al. Meningococcal group W disease in infants and potential prevention by vaccination. Emerg Infect Dis 2016; 22: 1505-1507.
- 14. Public Health England. Incidence of invasive meningococcal infections laboratory reports in England, by age group and epidemiological year, 2006/07-2015/16. Oct 2017. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/563523/Figure_1_Incidence_of_laboratory_confirmed_cases_of_meningococcal_disease_in_England_by_age_group_and_epi_year.pdf (accessed May 2017).
- 15. Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet 2016; 388: 2775-2782.
- 16. Kapur S, Bourke T, Maney JA, Moriarty P. Emergency department attendance following 4-component meningococcal B vaccination in infants. Arch Dis Child 2017; 102: 899-902.
- 17. Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother 2014; 10: 1993-2004.
- 18. Scheme TPB. Multicomponent meningococcal group B vaccine, 0.5mL, injection, prefilled syringe, Bexsero® — November 2013 [public summary document]. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2013-11/meningococcal-vaccine (accessed July 2017).
- 19. Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J Paediatr Child Health 2001; 37: S13-S19.
Hannah Christensen is supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Evaluation of Interventions at the University of Bristol, in partnership with Public Health England. The views expressed in this article are those of the authors and do not necessarily reflect those of the National Health Service, the NIHR, the Department of Health, or Public Health England.
Andrew Pollard has conducted studies on behalf of Oxford University funded by vaccine manufacturers, but does not currently undertake industry-funded clinical trials. Trials of vaccines or observational studies previously funded by Okairos, Novartis and Pfizer were completed in the past 3 years. His department received unrestricted educational grants from Pfizer/GSK/Astra Zeneca in July 2016 for a course on Infection and Immunity in Children. Andrew Pollard chairs the United Kingdom Department of Health Joint Committee on Vaccination and Immunisation, and is a member of the World Health Organization Strategic Advisory Group of Experts. Hannah Christensen has received an honorarium from Sanofi Pasteur, and consultancy fees from IMS Health, AstraZeneca, and GSK, all paid to her employer.